Literature DB >> 18980971

SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2.

Pornchai O-charoenrat1, Inderpal Sarkaria, Simon G Talbot, Pabbathi Reddy, Su Dao, Ivan Ngai, Ashok Shaha, Dennis Kraus, Jatin Shah, Valerie Rusch, Y Ramanathan, Bhuvanesh Singh.   

Abstract

PURPOSE: Ectopic expression of squamous cell carcinoma-related oncogene (SCCRO or DCUN1D1) in NIH-3T3 cells induces invasion in vitro and produces highly invasive xenografts in nude mice with a propensity for regional lymphatical metastasis. The aim of this study was to identify the molecular mechanism underlying SCCRO-induced invasion and metastasis. EXPERIMENTAL
DESIGN: The molecular mechanism of SCCRO-mediated effects on matrix metalloproteinase-2 (MMP2) levels and activity were assessed using a combination of cell biological and molecular methods, including real-time PCR, reporter assay, RNA interference, and chromatin immunoprecipitation assay. Tumor specimens from primary upper aerodigestive tract carcinomas (n = 89) were examined for levels of SCCRO, MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA by real-time PCR.
RESULTS: Overexpression of SCCRO increases MMP2 levels and activity, which is required for SCCRO-induced invasion. Modified McKay assays reveal that SCCRO does not bind to the MMP2 promoter, suggesting that its transcriptional effects are indirect. Deletion or mutation of the activator protein-2 (AP2) and p53 binding element within the MMP2 promoter abrogates SCCRO-driven activation. Ectopic expression of SCCRO increases AP2 levels and promotes the binding of p53 to the MMP2 promoter. Consistent with these findings, SCCRO and MMP2 are coexpressed (P<0.0001; r(2)=0.58; 95% confidence interval, 0.46-0.69) in primary (upper aerodigestive tract) carcinomas (n=89), and this coexpression is associated with an increased prevalence of regional nodal metastasis (P=0.04; relative risk, 1.53).
CONCLUSIONS: SCCRO-induced invasion involves activation of MMP2 transcription in an AP2- and p53-dependent manner. SCCRO is a potential marker for metastatic progression in affected cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980971     DOI: 10.1158/1078-0432.CCR-08-0719

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

1.  SCCRO promotes glioma formation and malignant progression in mice.

Authors:  Stephen R Broderick; Benjamin J Golas; Duykhanh Pham; Christopher W Towe; Simon G Talbot; Andrew Kaufman; Sarina Bains; Laryssa A Huryn; Yoshihiro Yonekawa; Diane Carlson; Dolores Hambardzumyan; Yegnanarayana Ramanathan; Bhuvanesh Singh
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

2.  Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation.

Authors:  Ho Shin Kim; Jared T Hammill; Daniel C Scott; Yizhe Chen; Jaeki Min; Jonah Rector; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2019-09-13       Impact factor: 7.446

3.  Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Daniel C Scott; Jaeki Min; Michele C Connelly; Gloria Holbrook; Fangyi Zhu; Amy Matheny; Lei Yang; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

4.  Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Deepak Bhasin; Daniel C Scott; Jaeki Min; Yizhe Chen; Yan Lu; Lei Yang; Ho Shin Kim; Michele C Connelly; Courtney Hammill; Gloria Holbrook; Cynthia Jeffries; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

5.  SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.

Authors:  Thomas Hussenet; Soraya Dali; Julien Exinger; Ben Monga; Bernard Jost; Doulaye Dembelé; Nadine Martinet; Christelle Thibault; Joerg Huelsken; Elisabeth Brambilla; Stanislas du Manoir
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

6.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

7.  Immunohistochemical Expression of DCUN1D1 in Non-small Cell Lung Carcinoma: Its Relation to Brain Metastasis.

Authors:  Jinyoung Yoo; Seong-Hak Lee; Kwang-Il Lym; Sonya Youngju Park; Seung-Ho Yang; Chang-Young Yoo; Ji-Han Jung; Seok-Jin Kang; Chang-Suk Kang
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

8.  Vaginal Stump Ligation for Cervical Cancer.

Authors:  Yanling Yang; Yang Liu; Guilin Li; Lei Li; Peng Geng; Hongjuan Song
Journal:  Iran J Public Health       Date:  2017-10       Impact factor: 1.429

9.  MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1.

Authors:  Yu Shuang; Chao Li; Xuan Zhou; Yongwang Huang; Lun Zhang
Journal:  Oncol Rep       Date:  2017-08-03       Impact factor: 3.906

Review 10.  [Research advances of artemin].

Authors:  Guangsu Xun; Fengjie Guo; Zhigang Li; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.